GlobeNewswire: Akers Biosciences Inc. Contains the last 10 of 102 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T14:07:12ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2020/08/27/2084832/0/en/Akers-Biosciences-and-Premas-Biotech-Announce-SARS-CoV-2-Positive-Proof-of-Concept-Results.html?f=22&fvtc=4&fvtv=20853Akers Biosciences and Premas Biotech Announce SARS CoV-2 Positive Proof of Concept Results2020-08-27T13:00:00Z<![CDATA[Thorofare, New Jersey, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced with its partner, Premas Biotech, positive proof of concept results from Animal Studies conducted during a 4 week test of its SARS-CoV-2 vaccine candidate in mice. The test had two primary endpoints, safety and immune response, both of which were met. The candidate was well tolerated and safe in mice that received the intramuscular injection. A robust immune response was also observed.]]>https://www.globenewswire.com/news-release/2020/08/11/2076327/0/en/Akers-Biosciences-Announces-6-8-Million-Registered-Direct-Offering-Priced-At-the-Market-under-Nasdaq-Rules.html?f=22&fvtc=4&fvtv=20853Akers Biosciences Announces $6.8 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules2020-08-11T12:00:00Z<![CDATA[Thorofare, New Jersey, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 1,207,744 shares of the Company’s common stock, at a purchase price of $5.67 per share, in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about August 13, 2020, subject to the satisfaction of customary closing conditions.]]>https://www.globenewswire.com/news-release/2020/07/07/2058642/0/en/Akers-Biosciences-and-Premas-Biotech-Announce-Initiation-of-Animal-Studies.html?f=22&fvtc=4&fvtv=20853Akers Biosciences and Premas Biotech Announce Initiation of Animal Studies2020-07-07T13:00:00Z<![CDATA[Company intends to cease focus on screening and testing products business]]>https://www.globenewswire.com/news-release/2020/05/18/2035286/0/en/Akers-Biosciences-Closes-4-8-Million-Registered-Direct-Offering-Priced-At-the-Market-under-Nasdaq-Rules.html?f=22&fvtc=4&fvtv=20853Akers Biosciences Closes $4.8 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules2020-05-18T21:33:29Z<![CDATA[Thorofare, New Jersey, May 18, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced the closing of its previously announced registered direct offering of an aggregate of 1,366,856 shares of the Company’s common stock, at a purchase price of $3.53 per share priced at-the-market under Nasdaq rules.]]>https://www.globenewswire.com/news-release/2020/05/14/2033758/0/en/Akers-Biosciences-Announces-4-8-Million-Registered-Direct-Offering-Priced-At-the-Market-under-Nasdaq-Rules.html?f=22&fvtc=4&fvtv=20853Akers Biosciences Announces $4.8 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules2020-05-14T17:00:00Z<![CDATA[Thorofare, New Jersey, May 14, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 1,366,856 shares of the Company’s common stock, at a purchase price of $3.53 per share, in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about May 18, 2020, subject to the satisfaction of customary closing conditions.]]>https://www.globenewswire.com/news-release/2020/05/14/2033608/0/en/Akers-Biosciences-and-Premas-Biotech-Announce-Successful-Completion-of-Vaccine-Prototype-Obtained-First-Images-of-VLP.html?f=22&fvtc=4&fvtv=20853Akers Biosciences and Premas Biotech Announce Successful Completion of Vaccine Prototype & Obtained First Images of VLP2020-05-14T13:33:01Z<![CDATA[Thorofare, New Jersey, May 14, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that Premas Biotech, its partner in the development of a vaccine candidate that is seeking to address the COVID-19 pandemic, has successfully completed its vaccine prototype. Premas obtained transmission electron microscopic (TEM) images of the recombinant virus like particle (VLP) assembled in yeast during the past week which marks a significant milestone and is believed by Premas to be one of the first in the world for VLP of SARS-CoV-2 virus. Premas, which is primarily responsible for the development of the vaccine candidate through proof of concept, is collating data at this time and, collectively with Akers, moving forward with conversations with regulatory authorities in India and continuing to develop a regulatory strategy in the United States. A manufacturing protocol has also been established and large-scale production studies have been initiated for the vaccine candidate.]]>https://www.globenewswire.com/news-release/2020/04/08/2013658/0/en/Akers-Biosciences-and-Premas-Biotech-Announce-Successful-Expression-of-Coronavirus-Antigens.html?f=22&fvtc=4&fvtv=20853Akers Biosciences and Premas Biotech Announce Successful Expression of Coronavirus Antigens2020-04-08T13:25:00Z<![CDATA[Thorofare, New Jersey, April 08, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that its collaboration with Premas Biotech has successfully completed a second milestone, the successful expression of the three coronavirus antigens, Spike (S), Envelope (E), and Membrane (M), that were selected for their vaccine candidate. The antigens have been expressed using the D-CryptTM platform at Premas Biotech, which utilizes its vectors and S cerevisiae strain. Premas is now moving forward with purification and post-expression processing, which we believe should lead to a scaling up of the antigens.]]>https://www.globenewswire.com/news-release/2020/04/07/2012970/0/en/Akers-Biosciences-Announces-4-6-Million-Registered-Direct-Offering-Priced-At-the-Market-under-Nasdaq-Rules.html?f=22&fvtc=4&fvtv=20853Akers Biosciences Announces $4.6 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules2020-04-07T14:53:24Z<![CDATA[Thorofare, New Jersey, April 07, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 766,667 shares of the Company’s common stock, at a purchase price of $6.00 per share, in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about April 9, 2020, subject to the satisfaction of customary closing conditions.]]>https://www.globenewswire.com/news-release/2020/04/06/2012184/0/en/Akers-Biosciences-and-Premas-Biotech-Announce-Progress-in-its-Vaccine-Development-for-Covid-19.html?f=22&fvtc=4&fvtv=20853Akers Biosciences and Premas Biotech Announce Progress in its Vaccine Development for Covid-192020-04-06T13:25:00Z<![CDATA[Thorofare, New Jersey, April 06, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that its collaboration with Premas Biotech has successfully completed the milestone of obtaining clones of all three coronavirus antigens, Spike (S), Envelope (E), and Membrane (M) that they have selected for their vaccine candidate.]]>https://www.globenewswire.com/news-release/2020/03/24/2005839/0/en/Akers-Biosciences-Schedules-Conference-Call-to-Discuss-Licensing-Announcement-with-Premas-Biotech-for-a-Coronvirus-Vaccine-Candidate.html?f=22&fvtc=4&fvtv=20853Akers Biosciences Schedules Conference Call to Discuss Licensing Announcement with Premas Biotech for a Coronvirus Vaccine Candidate2020-03-24T20:06:15Z<![CDATA[Thorofare, New Jersey, March 24, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced it will hold a conference call to discuss the licensing announcement with Premas Biotech for a Coronvirus vaccine candidate.]]>